Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Dexcom Inc (NASDAQ: DXCM) closed at $67.47 down -0.15% from its previous closing price of $67.57. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 2.69 million shares were traded. DXCM stock price reached its highest trading level at $68.18 during the session, while it also had its lowest trading level at $67.12.
Ratios:
For a deeper understanding of Dexcom Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.78. For the most recent quarter (mrq), Quick Ratio is recorded 1.38 and its Current Ratio is at 1.56. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.49.
On November 25, 2025, Evercore ISI started tracking the stock assigning a In-line rating and target price of $68.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 14 ’25 when Collins Richard Alexander sold 2,906 shares for $59.05 per share. The transaction valued at 171,599 led to the insider holds 35,088 shares of the business.
Collins Richard Alexander bought 2,906 shares of DXCM for $171,599 on Nov 14 ’25. On Nov 12 ’25, another insider, Heller Bridgette P, who serves as the Director of the company, sold 1,012 shares for $58.07 each. As a result, the insider received 58,767 and left with 27,031 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 26458716160 and an Enterprise Value of 25567897600. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.55, and their Forward P/E ratio for the next fiscal year is 27.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.83 while its Price-to-Book (P/B) ratio in mrq is 9.65. Its current Enterprise Value per Revenue stands at 5.662 whereas that against EBITDA is 25.015.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.49, which has changed by -0.13115597 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $93.25, while it has fallen to a 52-week low of $54.11. The 50-Day Moving Average of the stock is 5.16%, while the 200-Day Moving Average is calculated to be -8.76%.
Shares Statistics:
For the past three months, DXCM has traded an average of 5.98M shares per day and 4782290 over the past ten days. A total of 390.00M shares are outstanding, with a floating share count of 384.35M. Insiders hold about 1.45% of the company’s shares, while institutions hold 95.97% stake in the company. Shares short for DXCM as of 1765756800 were 13117820 with a Short Ratio of 2.19, compared to 1763078400 on 13410567. Therefore, it implies a Short% of Shares Outstanding of 13117820 and a Short% of Float of 4.32.
Earnings Estimates
At present, 23.0 analysts are actively evaluating the performance of Dexcom Inc (DXCM) in the stock market.The consensus estimate for the next quarter is $0.47, with high estimates of $0.55 and low estimates of $0.4.
Analysts are recommending an EPS of between $2.17 and $1.96 for the fiscal current year, implying an average EPS of $2.06. EPS for the following year is $2.48, with 25.0 analysts recommending between $2.68 and $2.29.
Revenue Estimates
A total of 23 analysts believe the company’s revenue will be $1.24B this quarter.It ranges from a high estimate of $1.25B to a low estimate of $1.22B. As of. The current estimate, Dexcom Inc’s year-ago sales were $1.11BFor the next quarter, 23 analysts are estimating revenue of $1.18B. There is a high estimate of $1.26B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 26 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.67B, while the lowest revenue estimate was $4.61B, resulting in an average revenue estimate of $4.64B. In the same quarter a year ago, actual revenue was $4.03BBased on 26 analysts’ estimates, the company’s revenue will be $5.23B in the next fiscal year. The high estimate is $5.35B and the low estimate is $5.14B.
